Fresenius Kabi and Baxter Healthcare Corp. will supply almost $65 million in drugs to the national medical stockpile to treat patients with Covid-19 and prepare for future emergencies.
The Strategic National Stockpile is purchasing the pharmaceuticals as part of a plan to restructure and resupply, known as SNS 2.0, so that there are enough in the case of future Covid-19 flare-ups.
Fresenius was awarded a contract worth $35 million, and Baxter was awarded a contract worth $29.9 million. The Department of Health and Human Services previously awarded contracts to the two companies to supply $16 million in vital ICU drugs ...